| Patient | Yul Brynner |
|---|---|
| Date of birth | 1920-07-11 |
| Identifiers | MRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572 |
| Document date | 1983-09-15 |
| Author | Simon Achterberg, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis and staging review. [S]
Mr. Brynner returns two weeks after his first visit. His PET-CT and brain MRI were done eleven days ago, and the endobronchial ultrasound biopsy six days ago. He saw the thoracic oncologist this morning and was told he has adenocarcinoma of the lung that has spread to three bones. His voice is still weak and breathy, and he has not sung since the tour paused. He has a little dry cough in the mornings, no blood in his sputum, and no breathlessness on the level. He has no bone, back, rib, or hip pain, no headache, and no weakness or numbness. His weight is steady. He is sleeping less well with worry, but he says he wants every fact and wants to get back on stage. He has not smoked for 12 years. [S]
| Element | Detail |
|---|---|
| Results since last visit | PET-CT and brain MRI; endobronchial ultrasound biopsy: adenocarcinoma, PD-L1 70 percent; plasma testing without an actionable alteration; tissue sequencing pending |
| Voice | Weak and breathy; not singing |
| Respiratory | Morning dry cough; no hemoptysis; no breathlessness on the level |
| Bone and neurological symptoms | None |
| Coping | Worried and sleeping less; distress thermometer 6 of 10 |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Morning dry cough; breathless on two flights of stairs; no hemoptysis |
| Musculoskeletal | Negative | No bone, back, rib, or hip pain |
| Neurological | Negative | No headache, weakness, numbness, or unsteadiness |
| Psychiatric | Positive | Worried; sleeping about five hours; no thoughts of self-harm |
4 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1983-09-15 | Body height | 178 | cm | S |
| 1983-09-15 | Body weight | 72 | kg | S |
| 1983-09-15 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 1983-09-15 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1983-09-15 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1983-09-15 | Heart rate | 80 | /min | S |
| 1983-09-15 | Respiratory rate | 16 | /min | S |
| 1983-09-15 | Body temperature | 36.7 | Cel | S |
| 1983-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1983-09-15 | Total score [Edmonton Symptom Assessment System] | 18 | {score} | S |
Vital signs recorded on 1983-09-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Upright and composed; weight 72.0 kg |
| Voice | Breathy, low-volume voice; short phonation time |
| Lungs | Slightly reduced breath sounds at the left apex; no wheeze or crackles |
| Lymph nodes | No supraclavicular or cervical nodes |
| Spine and pelvis | No tenderness over T10, the ribs, or the right iliac crest |
| Neurological | Normal strength, sensation, and gait |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed | C34.12 | S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983. |
| Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer. |
| Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed | J38.01 | S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor. |
| Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed | R91.8 | S — Synthetic presenting imaging finding, recorded before the tissue diagnosis. |
| Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed | Z87.891 | S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PD-L1 immunohistochemistry (tumor proportion score) | At diagnosis; repeat at progression | Completed today | 22C3 assay on the endobronchial ultrasound sample: tumor proportion score 70 percent |
| Laboratory | Broad molecular profiling (tissue and plasma) | At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progression | Ordered | Plasma cell-free DNA: no actionable alteration. Tissue next-generation sequencing pending; therapy waits for it |
| Imaging | Staging PET-CT and brain MRI | At diagnosis of suspected advanced disease | Completed today | Reviewed today: cT4 N2 M1c (bone), no brain metastases |
| Laboratory | Immune-related adverse event laboratory panel | Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated | Due | Baseline panel before the first infusion |
| Imaging | Response assessment imaging | Every 6 to 12 weeks on active systemic therapy | Not indicated | No systemic therapy started yet |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Morning dry cough; breathless on two flights of stairs; no hemoptysis |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco for 12 years |
| Survey | Distress and symptom screening (NCCN Distress Thermometer, ESAS) | Every visit; at minimum at key transitions | Completed today | Distress thermometer 6 of 10 (worry, work, voice); ESAS total 18 |
| Survey | Cancer-related fatigue screening | Every visit | Completed today | Tires by evening; ESAS tiredness 4 of 10 |
| Survey | Depression and anxiety screening | At least yearly; more often during active treatment | Up to date | PHQ-9 5 two weeks ago; rescreen during treatment |
| Examination | Weight and dietary review | Each follow-up | Completed today | 72.0 kg, stable; eating normally |
| Medication safety | Dental evaluation before a bone-modifying agent | Baseline, then periodically on zoledronic acid or denosumab | Due | Dental examination booked for Friday |
| Medication safety | Chemotherapy-induced peripheral neuropathy | Every visit during and after platinum or taxane | Not indicated | No platinum or taxane planned |
| Referral | Thoracic oncology consultation | At diagnosis | Completed today | Seen today; stage IVB confirmed; pembrolizumab planned if tissue sequencing shows no actionable alteration |
| Referral | Early integrated palliative care | Within eight weeks of diagnosis of advanced cancer | Referred | First visit in two weeks |
| Self-management | Advance care planning and goals of care | At diagnosis and at changes in health | Completed today | First conversation today: he wants full information and full treatment, and to return to the stage |
| Self-management | Voice and work support | As needed | Referred | Injection medialization and voice therapy arranged |
| Medication safety | Immunizations per ACIP | Yearly review | Due | Influenza, pneumococcal, zoster, COVID-19, and RSV to be reviewed at the preventive visit |
| Examination | Pulmonary rehabilitation | Before and after lung resection, or for symptomatic dyspnea or deconditioning | Not indicated | No resection; not deconditioned |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026)
Follow-up: Dental examination on Friday. Visit next week for the tissue sequencing result and the treatment start. Palliative care in two weeks. Voice injection in three weeks. Next scheduled visit 1983-09-22: biomarker results and start of first-line pembrolizumab. [S]